Oei, Shiao Li
Rieser, Thomas
Becker, Sarah
Groß, Jessica
Matthes, Harald
Schad, Friedemann
Thronicke, Anja http://orcid.org/0000-0002-6421-8290
Article History
Received: 7 June 2021
Accepted: 23 November 2021
First Online: 2 December 2021
Declarations
:
: This study complies with the principles laid down in the Declaration of Helsinki [CitationRef removed] and was approved by the ethics of the Medical Association Berlin (Berlin_Ethik-Kommission der Ärztekammer Berlin) on 2 April 2020 with the reference number Eth-05/20. This trial was registered at the German Clinical Trials Register (Trial registration number DRKS00021601) on 21 August 2020. Written informed consent will be obtained from all participants prior to study enrollment. All substantial protocol deviations or modifications will be communicated to the Ethics Committee and German Clinical Trials Register.
: Model consent forms will be provided on request.
: JG reports grants from Roche (honoraria for speaking). HM is a member of the board of directors of Weleda AG, a member of the Network Arbeitsgemeinschaft der Wissenschaftlichen Fachgesellschaften (AWMF e.V.) guideline committee for integrative oncology (Guideline for Complementary Medicine in the Treatment of Oncological Patients), and has an endowed professorship at the Charité Universitätsmedizin Berlin, which is financed by the Software AG Foundation, outside the submitted work. FS reports grants from Helixor Heilmittel GmbH (travel costs and honoraria for speaking), grants from AstraZeneca (travel costs and honoraria for speaking), grants from Abnoba GmbH, and grants from Iscador AG, outside the submitted work. The other authors declared that they have no competing interests. No payment was received for any other aspects of the submitted work. There are no patents, products in the development, or marketed products to declare. There are no other relationships/conditions/circumstances that present a potential conflict of interest.